COGT Cogent Biosciences, Inc.
COGT Cogent Biosciences, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 2 scans as of 2026-08-17 2 neutral converging
POC $37.59 · VWAP $32.01 · +18.3% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
3 watchlists
COGT Price Structure
Loading timeframes…
Peers
Every watchlist COGT belongs to, members best 30-day change first — COGT highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@ibb
@biotech-scan
@monster-discoveries
Decision history
1 scored call · newest first · projection
How to read this: Positive 30-day excess supports an enter call. For pass, avoid, sell, or exit calls, a positive number means the name kept rising after the call.
COVERAGE GAP — this name's print date has passed and tonight's bounded news pass (~25 marquee/tracked symbols) did not include it. No coverage was acquired; nothing is asserted about the result. Refill on the next daily or when the name earns a targeted pull.
full note →Against street estimates
How COGT's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about COGT from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 42 days ago · Jul 7
- Cogent Biosciences Announces Poster Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026
- Cogent Biosciences Announces Submission of New Drug Application for Bezuclastinib in Gastrointestinal Stromal Tumors (GIST)
- Cogent Biosciences Reports Recent Business Highlights and First Quarter 2026 Financial Results
- Cogent Biosciences Announces Oral Presentation of Positive Phase 3 PEAK Trial in Gastrointestinal Stromal Tumors (GIST) at the 2026 ASCO Annual Meeting
- Cogent Biosciences Announces Multiple Presentations at the European Hematology Association (EHA) 2026 Congress
“On or before” marks an article that arrived without a publish date — the date shown is when the desk pulled it, so the article is at least that old.
COGT research tape
32 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.